Trial Profile
A phase II study of erlotinib in benefitted patients with asymptomatic brain metastases advanced non-small cell lung cancer by chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Pharmacogenomic; Therapeutic Use
- 19 May 2008 New trial record.